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The public health implications of hepatitis E virus 
(HEV) in Europe have changed due to increasing num-
bers of hepatitis E cases and recent reports of chronic, 
persistent HEV infections associated with progression 
to cirrhosis in immunosuppressed patients. The main 
infectious risk for such immunosuppressed patients is 
exposure to undercooked infected pork products and 
blood transfusion. We summarised the epidemiology 
of HEV infections among blood donors and also out-
lined any strategies to prevent transfusion-transmit-
ted HEV, in 11 European countries. In response to the 
threat posed by HEV and related public and political 
concerns, most of the observed countries determined 
seroprevalence of HEV in donors and presence of HEV 
RNA in blood donations. France, Germany, Spain and 
the United Kingdom (UK) reported cases of transfu-
sion-transmitted HEV. Ireland and the UK have already 
implemented HEV RNA screening of blood donations; 
the Netherlands will start in 2017. Germany and France 
perform screening for HEV RNA in several blood estab-
lishments or plasma donations intended for use in 
high-risk patients respectively and, with Switzerland, 
are considering implementing selective or universal 
screening nationwide. In Greece, Portugal, Italy and 
Spain, the blood authorities are evaluating the situ-
ation. Denmark decided not to implement the HEV 
screening of blood donations.
Background
Hepatitis E is a liver disease caused by infection with 
a small, non-enveloped, single-stranded RNA virus 
known as hepatitis E virus (HEV). Of four major HEV 
genotypes which infect humans, genotypes 1 and 2 are 
endemic and responsible for waterborne epidemics. 
Genotypes 3 and 4 are associated with zoonotic HEV 
infections transmitted to humans through consump-
tion of raw or undercooked infectious pork and game 
products, and very rarely shellfish, or by contact with 
infected animals. The thermal resistance of HEV is rela-
tively high in food products. The virus is successfully 
inactivated at food internal temperatures > 71 °C for at 
least 20 min [1]. Some people are unaware that gam-
mon, sausages and salami may be cured but not cooked 
and therefore fall into the category of ‘uncooked meat’. 
Transmissions of HEV through transfusion and trans-
plantation have also been reported [2,3].
A substantial increase of locally acquired HEV cases 
is observed across Europe where HEV genotype 3 
infections, originating from animal reservoirs, are 
predominant and have become a common cause of 
acute viral hepatitis [4,5]. To analyse the trend in the 
incidence and prevalence of HEV infection in Europe, 
there is a need for harmonised case definition, sur-
veillance system and testing algorithms [5]. HEV gen-
otype 3 infection is commonly asymptomatic or mild 
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and self-limiting without chronic sequelae [6]. Acute 
phase viraemia typically persists for 6 to 8 weeks, and 
because most cases are asymptomatic, it is possible 
for infected blood donors to donate while viraemic. A 
high frequency of viraemic donations, of up to 1:726 
[7], has been detected in several European countries 
using nucleic acid testing (NAT). The number of notified 
transfusion-transmitted HEV (TT-HEV) infections has 
until now been very low, probably due to under-report-
ing and under-recognition mainly because of asymp-
tomatic infections in transfusion recipients. All types 
of blood components including solvent–detergent (SD) 
treated plasma have been implicated in transmission. 
One United Kingdom (UK) study [8] retrospectively 
screened blood donations in pools of 24 samples and 
showed that one in 2,830 blood donations was HEV 
RNA positive. Follow-up of transfused HEV RNA posi-
tive blood components showed a 42.0% transmission 
rate, with transmission probability linked to viral load 
and absence of anti-HEV antibodies. Although HEV 
RNA was detected in plasma fractionation pools from 
Europe, Asia and North America, HEV transmission 
through plasma-derived medicinal products has not 
been observed [9]. The European Medicines Agency 
published a reflection paper on viral safety of plasma 
derived medicinal products with respect to HEV [10].
HEV genotype 3-related severe cases of hepatitis and 
chronic liver disease, occasionally leading to cirrhosis, 
have been reported in immunosuppressed transplant 
recipients, patients with haematological disorders and 
patients with underlying liver disease. Such patients 
are exposed to HEV primarily via daily dietary sources. 
Exposure to HEV through blood components is lower 
than dietary exposure in patients who have limited 
transfusion needs, but the risk of transmission through 
transfusion rises in the multi-transfused. One model 
estimates that receiving blood components from 13 
donors carries a similar risk to 1 year of dietary expo-
sure [11]. Prolonged viraemia and chronic liver injury 
can often be resolved by administration of ribavirin or 
reducing the level of immunosuppression [12]. The lat-
ter is challenging in haematological patients suffering 
from graft vs host disease and requiring more aggres-
sive immunosuppressive therapy.
The European Pharmacopoeia requires HEV RNA screen-
ing of plasma pools for the production of SD plasma 
[13]. In response to a threat posed by HEV to transfu-
sion safety and related public, political and reputa-
tional concerns, Ireland and the UK respectively have 
also implemented universal or selective (screening of 
donations for immunosuppressed recipients) screen-
ing of blood donations for the presence of HEV RNA, 
and others are considering doing so. Hepatitis E infec-
tion is not currently reportable under the provisions of 
European Union (EU) legislation [5].
Here we summarise the epidemiology of HEV infec-
tions among blood donors, along with that of reported 
cases of hepatitis E among patients, and also outline 
any strategies to prevent TT HEV, in 11 European coun-
tries (in alphabetical order) that were discussed during 
a European Centre for Disease Prevention and Control 
(ECDC) expert meeting in Lisbon, Portugal in May 2016.
Hepatitis E virus and blood donations in 
selected European countries
Denmark
Denmark has a large pig-farming industry and asso-
ciated production of pig products. An investigation 
among pig herds in 2010 found HEV genotype 3 in the 
stools of more than 50% of herds investigated [14]. 
In 2013, a seroprevalence study among Danish blood 
donors showed 10% to 20% anti-HEV IgG positivity, 
depending on the assay used, and found an increase 
with age. Compared with seroprevalence studies of 
samples from Danish donors in 2003 and 1983, the 
authors found a declining prevalence corresponding to 
a birth cohort phenomenon [15].
In a Danish nationwide investigation, ca 25,000 dona-
tions from 2015 were screened for HEV RNA by Single 
Donation nucleic acid testing (NAT) (Grifols). The 
prevalence of HEV RNA positive donations was 1:2,331 
(0.04%) [16], consistent with data from other northern 
European countries (Table). Positive donations had a 
median viral load of 13 IU/mL in a range from unquan-
tifiable to 920 IU/mL [16]. Look-back studies of living 
recipients found no evidence of TT HEV infections [16]. 
Based on these data, the Danish Society of Clinical 
Immunology does not recommend the screening of 
blood donations for HEV in Denmark [17].
France
HEV RNA NAT screening (pools of 96 samples) of 
plasma donations for subsequent solvent–detergent 
treatment in the period 2012/13 showed an HEV RNA 
positive detection rate of 0.04% (24/53,234) or 1:2,218 
donations [18]. Most samples (22/24) from viraemic 
donors were negative for anti-HEV IgG and IgM. HEV 
genotype 3 was detected with viral loads from 468 
to 5.1 106 IU/mL. Recent data obtained from plasma 
donations screened by minipools (6 samples) indicate 
a higher rate of positive donations (ca 1:1,000). A sero-
prevalence study of 10,569 blood donations collected 
in mainland France and three overseas territories gave 
overall IgG (Wantai) prevalence 22.4% (range 8.0% to 
86.4%) [19]. Significant geographical difference and 
hyperendemic areas in the southern part of France 
were found. IgG HEV seropositivity was associated 
with increasing age, eating pork meat, pork liver sau-
sages, game meat, offal, and oysters, while drinking 
bottled water appeared protective. IgM seroprevalence 
was 1% (0–4.6%) [19]. Between 2006 and 2013, 16 
cases of TT HEV genotype 3 were reported, mostly in 
immunocompromised solid organ transplant recipients 
as well as patients with haematologic malignancies 
under chemotherapy treatment, and confirmed by viral 
strain comparison. All types of blood components, 
including plasma treated by amotosalen and ultraviolet 
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illumination, were implicated in transmission events 
[20]. Five cases of chronic HEV infection required riba-
virin treatment [21]. Since 2013 the fraction of plasma 
collected by the French Blood Service that is intended 
for use in high-risk patients is screened for HEV RNA. 
NAT screening of blood donations is under considera-
tion by the French health authorities.
Germany
There has been a marked increase of notified cases, 
from 670 in 2014 to 1,267 in 2015 [22]. The reason for 
this increase is unknown, but could be due to grow-
ing awareness and testing by physicians. Studies in 
Germany found from 1:679 to 1:4,252 blood donations 
to be HEV RNA positive [23-25]. So far, five TT HEV 
infections have been reported in the German hae-
movigilance database, two in 2013 and three in 2014 
[26]. Four cases were asymptomatic. In one case, HEV-
infection was considered a co-factor leading to serious 
complications in a haematopoietic stem cell transplant 
patient suffering from severe graft vs host disease 
[27]. An analysis of transfusion-associated cases from 
2015 has not been finalised, but three probable or con-
firmed TT cases were reported. One lymphoma patient 
receiving HEV RNA-positive transfusions after trans-
plantation developed chronic hepatitis E. Two cases 
were asymptomatic. One additional case is still being 
investigated. Monitoring of immunocompromised 
patients, especially transplant recipients, for HEV 
infection is recommended by the German Advisory 
Committee Blood (Arbeitskreis Blut) [28]. Screening of 
blood donors has not been recommended but is under 
discussion [28]. As of December 2016, six blood estab-
lishments in Germany notified the German Competent 
Authority that they have commenced voluntary screen-
ing of blood donations for HEV RNA.
Greece
In a recent study [29], archived blood samples from 
1,835 blood donors, and recent samples from 249 
thalassaemic patients from nine Greek regions were 
examined for anti-HEV antibodies using commercial 
ELISA and immunochromatographic tests. HEV RNA 
was tested for using the Procleix HEV (Grifols) assay 
in 1,813 blood samples from 1,670 blood donors and 
143 thalassaemic patients. HEV IgG antibodies were 
present in 2.9% of blood donors. Seroprevalence was 
higher in older donors (5.9% in those aged > 50 years 
vs 1.8% in younger donors). The highest seropreva-
lence of 13.3% among male blood donors was found 
in Heraklion, Crete. Seroprevalence in thalassaemic 
patients was 3.6%. Results of HEV RNA testing among 
donors are not yet available. The data showed that the 
current seroprevalence of HEV in blood donors was 
lower in comparison to other European regions but 
showed an increasing trend. Donors’ age and sex were 
Table
Prevalence of hepatitis E virus RNA positive donations, population of transplanted patients at risk, reported cases of 
transfusion-transmitted hepatitis E virus and screening of blood donations in 11 European countries
Country HEV RNA positive donations
Population at risk Reported 
TT HEV 
infections











Denmark 1:2,331(2016) [16] 144 (201 – 300) 356 (63.6) x
France 1:2,218 (2012–3) [18]
1,724 (201 
– 300) 5,141(79.6) x x
a
Germany 1:1,241 (2012) [24] 2,892 (> 300) 3,710 (44.9) x xb
Greece NA 169 (151 – 200) 171 (15.4) x
Ireland 1:2,778 (2016) 77(151 – 200) 246 (52.3) xc
Italy NA 1,625 (201 – 300) 3,252 (53.2) x
The 
Netherlands 1: 726 (2016) [7] 1175 (> 300) 1,315 (78.3) x 
d/e
Portugal NA 137 (101 – 150) 739 (69.7) x
Spain 1:3,333 (2014) [53] 1,072 (201 – 300) 4,247 (90.2) x x






– 300) 4,561 (71.8) x x
e/f
allo-HSCT: allogeneic haematopoietic stem cell transplant patients; AN: annual number; AR: annual rate; HEV: hepatitis E virus; NA: not 
available, pmp: per million population; SOT: solid organ transplant patients; TT: transfusion-transmitted.
a Testing part of plasma production for use in patient at risk.
b Screening of all blood donations in some blood centres.
c Universal screening.
d Screening of plasma for the production of solvent-detergent treated plasma for clinical use.
e Universal screening planned for 2017.
f Selective screening.
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significant factors affecting the prevalence estimates. 
Most of the cases were imported from endemic coun-
tries outside Europe although the local acquisition of 
HEV requires further investigation in Heraklion.
Ireland
Ireland implemented universal HEV individual-donation 
nucleic acid test (ID-NAT) screening of blood donations 
for an initial 3-year period from January 2016. By the 
end of April 2016, 47,229 donations had been screened 
using the Procleix HEV assay (Grifols). There were 27 
initially reactive donations (0.057%), of which 16 
(0.034%) were repeat reactive (RR) and 11 non-repeat 
reactive (NRR; 0.023%). Of the 16 RRs, 15 were con-
firmed using PCR testing (RealStar RT-PCR kit, Altona) 
and/or by serology (Wantai IgM and IgG assays). One 
RR sample was negative by PCR and serology but on 
follow-up 34 days later was PCR and IgM reactive. 
Overall, the majority of donors (11/15) were viraemic 
and seronegative at index donation. Results of geno-
typing are available so far for two confirmed cases 
which are genotype 3, phylogenetic group 2. Of the 11 
NRRs, one donation was confirmed as an HEV case who 
subsequently seroconverted 70 days later with IgM and 
IgG reactivity. Eight NRRs have been confirmed as false 
positives, and two were awaiting follow-up testing at 
the time of writing this report. Of the 17 confirmed 
cases that occurred randomly across Ireland, 15 were 
male, and two were female. Episodic periods of reac-
tivity with high levels of confirmed cases in January, 
early February, and mid-April were observed. The HEV 
RNA prevalence in Irish donations is currently 1:2,778, 
which is higher than expected from the previous study 
(anti-HEV IgG positive 5.3% in 2012 and an HEV RNA 
positivity of 1 in 5,000 donations in the period from 
December 2013 to June 2014 [30].
Italy
The seroprevalence of hepatitis E in the Italian general 
population was analysed in six of 20 Italian regions 
and ranged from 1.5% to 2.9% [31-37]. Most of these 
studies were conducted before 1999. From 2007 to 
2016, 144 cases of acute hepatitis E were notified to 
the Italian Surveillance System for Acute Viral Hepatitis 
[38]. Among 144 cases, 122 (84.7%) were male with a 
mean age of 40 years, 81 (56.6%) were Italian. The viro-
logical surveillance of 139 acute non-A, non-B, non-C 
hepatitis (cases negative for hepatitis A, B and C) 
from 2004 to 2016 showed that 48 (34.5%) cases were 
due to HEV. Genotyping of HEV RNA-positive samples 
revealed that 55% (22/40) of patients were infected 
with genotype 1 and 45% (18/40) with genotype 3. 
The prevalence of HEV antibodies in blood donors 
from Abruzzo and Lazio, two regions of central Italy, 
was 48.9% (153/313) and 9.0% (9/100) respectively in 
2014 [39]. In Lazio, the seroprevalence of 9.0% in the 
donor population in 2014 is significantly higher than 
previously reported in the general population (2.6% in 
1996 and 2.9% in 2007), which strongly suggests an 
increasing trend of HEV infection in the general popu-
lation over almost two decades. The very high HEV IgG 
prevalence in blood donors from Abruzzo indicates 
that HEV infection is commonly acquired in this area. 
Seroprevalence increased with age and was associated 
with consumption of raw dried pork liver sausages. 
Among the IgG positive blood donors (n = 153) from 
Abruzzo, two (1.3%) were positive for IgM, and two 
(1.3%) were positive for HEV RNA; genotype 3 (subtype 
3c) [39]. A national survey in 2016–2017 will evaluate 
the prevalence of HEV infection in 10,000 blood dona-
tions in Italy (270 Blood Transfusion Centres from 20 
Italian regions). The results of the survey will be con-
sidered in developing HEV prevention strategy.
The Netherlands
Since 2012, between 2,000 and 4,000 Dutch plasma 
donations have been screened each month by PCR on 
pools of 96 donations for the presence of HEV. Overall 
79/101,793 or 1:1,289 donations were confirmed HEV 
RNA positive. HEV RNA sequencing shows HEV geno-
type 3 subtypes is present in Dutch hepatitis E patients 
and Dutch pigs [7]. This silent outbreak of HEV appears 
to be strikingly benign (i.e. lack of morbidity in neo-
nates/infants up to the age of 12 months, children, and 
pregnant women). Cases of chronic hepatitis E have 
been reported in haematological and organ transplant 
patients. The dietary routes of HEV transmission in the 
Netherlands have not yet been thoroughly investigated. 
Recently, 43 of 55 liver sausages and 12 of 15 liver pâté 
samples were found to be positive for HEV RNA by PCR 
[40]. The Dutch Food Safety Authority has confirmed 
these findings, and haematological and organ trans-
plant patients are advised to avoid these food items 
[40]. Although blood and blood components are prob-
ably a minor source of HEV infection in the Netherlands 
compared with dietary exposure, the presence of HEV-
positive donations in the blood supply has given rise to 
the expression of concerns about the safety profile of 
Dutch blood banking, such as indicated by the request 
of one academic hospital for the supply of HEV RNA-
screened blood.
HEV RNA screening of all Dutch blood donations is 
planned to start in July 2017. To provide HEV-screened 
blood for at-risk patients, 40% of Dutch donations 
must be screened. Considering the costs and the com-
plicated IT and logistical consequences of partial donor 
screening, universal HEV RNA donor screening is being 
considered as more feasible.
Portugal
HEV studies in Portugal are part of the HEPeCONTROL 
project (60DT2) under European Economic Area (EEA) 
grants funding [41]. Sera from a representative cohort 
of the Portuguese population (n = 1,656) distributed by 
geographic location (all 20 districts in Portugal), and 
5-year age group (ranging from 0 to 99 years of age) 
were collected between July 2015 and February 2016, 
and tested for the presence of anti-HEV IgG by EIA 
(recomWell HEV IgG, Mikrogen) [42]. An overall HEV IgG 
seroprevalence in the Portuguese population of 16% 
was found with seropositivity significantly increasing 
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with age (p < 0.05). Also, plasma samples from blood 
donors (n = 2,115) to a Blood Transfusion Service in 
Portugal collected between July 2015 and January 2016 
were tested individually for both anti-HEV IgM (recom-
Well HEV IgM, version 2015, Mikrogen) and HEV RNA, 
using two commercial real-time RT-PCR kits (ampliCube 
HEV 2.0, Mikrogen and RealStar HEV 1.0, Altona).
Among the 2,115 plasma samples, 7 (0.3%) were 
found to be positive for anti-HEV IgM but no RNA HEV 
was detected in any of the blood donors’ samples. 
HEPeCONTROL project has given a sufficient picture 
of HEV infection in Portuguese general population and 
blood donors necessary for a decision on the imple-
mentation of a HEV national prevention strategy in the 
future.
Spain
In 2013, the prevalence of anti-HEV IgG among 1,082 
blood donors from Catalonia was found to be 19.9% 
(Wantai) and 10.7% (Mikrogen). Screening of 9,998 
samples by HEV ID-NAT yielded three real-time PCR-
confirmed and IgM and IgG anti-HEV-positive dona-
tions with viral loads of 250, 564, and 2,755 IU/mL. The 
donation with highest viral load was genotype 3f. HEV 
RNA positivity rate was 1:3,333 donations (0.03%).
The first symptomatic TT HEV case in Spain was 
reported in 2015. The immunocompetent patient devel-
oped clinical and laboratory signs of acute hepatitis 
more than 1 month after transfusion of eight red cell 
units during and after surgery. Investigation showed 
that one transfused RBC unit was positive for HEV 
RNA with 100% identity with the recipient HEV RNA 
sequences. The implicated donor had occupational 
exposure in a sausage factory. Platelets from the same 
infected donation were transfused to a Hodgkin lym-
phoma patient who died shortly after transfusion [43]. 
Selective HEV screening of blood donations is under 
consideration taking into account logistical challenges. 
Blood banks from central and northern Spain plan to 
study HEV incidence.
Switzerland
A study of 550 donors from canton of Vaud in west-
ern Switzerland using three different HEV IgG EIAs 
(MP Diagnostics, Dia.Pro and Fortress) showed preva-
lences of 4.9%, 4.2% and 21.8% respectively [44]. An 
overall anti-HEV IgG seroprevalence of 8.9% (Mikrogen 
Diagnostic) in 1,484 donors was determined in the can-
ton of Zürich in eastern Switzerland [45]. A third study 
analysed 3,609 blood donors from all over Switzerland 
[46]. The HEV IgG (Wantai) prevalence ranged from 
12.8% (24/188) to 33.6% (116/345), depending on 
the geographical region. In the northern regions and 
within the Alps, seroprevalence seems to be quite 
similar (range: 12.8–24.8%) (24/188 to 69/278). In 
Ticino, a southern region of Switzerland, prevalence 
is higher with an average of 33.6% (116/345). In some 
smaller localities in Ticino, a prevalence bordering on 
50% (13/27) was observed. Unfortunately, to date, no 
incidence data for the Swiss general population or the 
blood donor population have been collected.
Avoidance of potentially contaminated food is recom-
mended to protect at-risk patients from dietary HEV 
infections. It is also proposed to screen blood dona-
tions for HEV RNA on pools of 96 samples and moni-
tor at-risk patients. Clinicians will also be informed of 
these specific measures in order to draw attention to 
future HEV infections in at-risk patients.
United Kingdom
Seroprevalence of anti-HEV IgG in 2015/2016 was 
found to be 11% (n = 13,042) in England and 6% 
(n = 1,700) in Scotland. There has been a steady 
increase in the incidence of acute cases since 2010 
associated with the emergence of a dominant clade 
(G3c). An increased anti-HEV IgG positivity in younger 
donors was observed in 2015/16. Surveillance data 
indicate a sudden increase in reported possible TT 
HEV cases in 2012 followed by a sustained rise from 
2015 onwards. Such growth probably resulted from a 
heightened clinical awareness, following the formation 
of an HEV working group of the Advisory Committee on 
Safety of Blood, Tissues and Organs (SaBTO). Reported 
cases of possible TT HEV were acute clinical hepati-
tis in immunocompetent individuals and silent infec-
tion in immunosuppressed haematopoietic stem cell 
and solid-organ transplant patients. A proportion of 
investigated cases were shown not to be transfusion-
associated. SaBTO recommended the provision of HEV-
screened blood components for recipients of allogeneic 
stem cell transplants and solid organ transplants [47]; 
the blood services additionally provide HEV-screened 
components for neonates/infants up to the age of 12 
months. A minimum of 30% of the blood supply is 
tested to meet current demand. As of May 2016, with 
blood donation screening using NAT RNA HEV test 
(pools of 24 samples), the number of confirmed RNA-
positive samples was 83 of 113,306 (1:1,365) tested in 
England, 10 of 12,504 (1:1,250) tested in Scotland, and 
2 of 4560 (1:2,280) in Wales. Look-back investigations 
are performed when blood donors are reported with 
acute HEV infection, but the donor HEV infection must 
be substantiated. The immediate previous donation 
of HEV RNA positive platelet donors is also subject to 
look-back. As of November 2016, the SaBTO has com-
pleted a review of HEV screening and its cost-effec-
tiveness and has recommended extending the use of 
screened components to other recipient groups and a 
change to universal screening of blood donations from 
April 2017 [48]. The principal drivers for this decision 
were technical complexity and costs of a double inven-
tory that was needed in selective screening.
Discussion
The public health implications of HEV in Europe have 
changed recently due to the increasing numbers of 
hepatitis E cases and reports of chronic, persistent HEV 
infections associated with progression to cirrhosis in 
immunosuppressed patients. The main infectious risks 
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for such immunosuppressed patients are dietary expo-
sure to pork products and transfusion. In the last dec-
ade, an increasing number of HEV genotype 3-positive 
donations have been documented in several European 
countries (Table). Such growth probably resulted from 
a heightened clinical awareness, and following on from 
national blood safety discussions and measures in 
some countries.
Taking into account the prevalence of HEV infection 
in pigs and pork meat consumption in the EU [49,50] 
on the one hand, and the incidence of HEV viraemic 
blood donations (Table) on the other, it seems that for 
the general population, the risk of HEV transmission 
via food products is considerably higher than through 
blood transfusion. Therefore, from a public health per-
spective, eliminating the dietary risk of HEV transmis-
sion is the most effective intervention and would also 
improve blood safety. Until and unless the dietary risk 
is eliminated, TT HEV infection in immunosuppressed 
patients represents a preventable cause of serious 
morbidity and mortality and as such indicates a need 
to improve transfusion safety.
Approaches to increase blood safety for HEV are cur-
rently limited. Potential measures include: pathogen 
inactivation of blood components, which may not yet be 
sufficiently effective for certain non-enveloped viruses 
such as HEV; immunisation of patients at risk, which is 
not yet available and is unproven against intravenous 
challenge; and screening of blood donations, which is 
an available intervention but not widely implemented 
because of effectiveness constraints and costs. In 
the absence of the implementation of such measures, 
individuals at risk of developing severe consequences 
remain exposed to the risk of TT HEV infection.
Universal screening of blood donations has been 
implemented in Ireland and selective screening imple-
mented in the UK in 2016. The majority of the other 
European countries assessed here, eight of 11, were 
at the time of the meeting investigating or considering 
the need to screen blood donations for the presence of 
HEV RNA. The UK and the Netherlands have, since the 
meeting, decided to implement universal screening in 
2017, as the most cost-effective way of ensuring provi-
sion of HEV screened blood components for the recom-
mended patient groups. Denmark has decided not to 
screen (Table).
The rationale for donation screening for any pathogen 
is particularly strong when there are specific recipient 
groups at risk of transfusion-transmitted infection. The 
population currently recognised to be at risk of TT HEV 
(recipients of solid organ and haematopoietic stem cell 
transplants, and other immunosuppressed patients) is 
relatively small in number (Table) but may receive sub-
stantial number of transfusions, which increases the 
probability of exposure and thus the risk of infection.
Justification of blood donation screening for HEV RNA 
becomes contentious if the risk from exposure of trans-
fusion recipients to dietary sources is not eliminated. 
Equally, some TT infections which cause disease in the 
immunosuppressed, such as parvovirus B19, remain 
tolerated and unscreened. In transfusion practice, 
however, laboratory screening of some pathogens (i.e. 
cytomegalovirus) has been implemented, despite a 
sustained community exposure of transfusion recipi-
ents. Thus, it seems that the risk of non-transfusion 
exposure to HEV might not be critical for a decision to 
implement HEV RNA screening of blood donations.
If implemented, screening may be selective, performed 
on blood donations intended for transfusion to patients 
at risk, or universally applied to all blood donations 
and subject to continuing review. Selective screening 
might be technically demanding especially with the 
management of the blood component inventory and is 
not necessarily less costly.
The decision to screen blood donations should be 
based on an assessment of the risk of TT HEV in the 
susceptible population, as determined by the back-
ground prevalence of transmissible infection in the 
donor population and the susceptibility of recipients. 
Further, to assess the absolute benefit of screening, 
detailed knowledge about the incidence of hepatitis E 
in patients receiving HEV-negative blood components 
and those who receive unscreened blood components 
is required. The costs as well as the benefits also need 
to be taken into account. Defining the appropriate sen-
sitivity level of NAT testing (pool size) is one of the key 
issues with an impact on the cost-effectiveness of rou-
tine screening.
Despite the uncertainties in the epidemiology of HEV, 
screening of blood donations for the presence of HEV 
RNA is clearly under consideration in several countries 
and has been currently implemented in two of those 
reviewed here. However, given what is known about 
the risks of dietary transmission of HEV infection, if 
implemented, the screening of blood donations should 
go hand in hand with raising clinicians’ awareness 
and strict dietary recommendation for patients at risk. 
Validation of NAT findings by seroconversion, sequenc-
ing of viral RNA genome using common sequence data-
base, and follow-up of HEV cases among blood donors 
and patients may help to define the relative contribu-
tions of different routes of HEV infection in Europe. 
Ultimately, addressing the root cause for viraemic 
pigs entering the human food chain will be required to 
achieve control of this zoonosis.
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